Document is current
Any future updates will be listed below
-
Authors
Colin-Leitzinger, Christelle https://orcid.org/0000-0002-8118-9591
Aranzabal, Olga
Johnson, Courtney E.
Alberg, Anthony J.
Bandera, Elisa V.
Bondy, Melissa
Cote, Michele L.
Hastert, Theresa A.
Haller, Kristin
Lawson, Andrew
Marks, Jeffrey R.
Peters, Edward S.
Terry, Paul D.
Schildkraut, Joellen M. https://orcid.org/0000-0002-0990-9339
Peres, Lauren C. https://orcid.org/0000-0002-6620-8600
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA142081)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA237318)
- License Information
-
More Information
Article History
Received: 28 March 2025
Revised: 26 September 2025
Accepted: 23 October 2025
First Online: 5 November 2025
Competing interests
: LCP reports research funding from Bristol Myers Squibb, Karyopharm and Janssen unrelated to this work. EVB served on a Pfizer Inc. Advisory Board to enhance minority participation in clinical trials unrelated to this work. No other conflicts of interest are reported by the other authors.
: Institutional Review Board approval was obtained at the parent institution (Duke University, University of Virginia) and each individual study site, and informed consent was obtained for all participants. The study was performed in accordance with the Declaration of Helsinki.
